Our data from the use of the three pharmacological inhibitors of STAT3 strongly support their use as promising drugs for the prevention or treatment of inflammatory or neoplastic diseases associated with laryngopharyngeal reflux. The gene discussed is STAT3; the disease is Laryngopharyngeal Reflux.